

OSIRIS THERAPEUTICS, INC.
Form 8-K
December 06, 2013

United States

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **December 2, 2013**

OSIRIS THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or other jurisdiction of
incorporation)

001-32966
(Commission File Number)

71-0881115
(IRS Employer
Identification No.)

7015 Albert Einstein Drive, Columbia, Maryland
(Address of principal executive offices)

21046
(Zip Code)

Registrant's telephone number, including area code: **(443) 545 - 1800**

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 5.02. Departures of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On December 2, 2013, C. Randal Mills, who has served as President and Chief Executive Officer of the Company since May 2004, resigned for personal reasons, effective the following day. Upon Dr. Mills' departure, Lode Debrabandere, the Company's Chief Operating Officer, assumed the additional roles of President and Chief Executive Officer, pending confirmation by the Board of Directors. Dr. Debrabandere has been an executive officer of the Company since July 2006. Dr. Mills concurrently resigned from the Company's Board of Directors.

Dr. Mills' compensation ceased upon the termination of his employment, consistent with the Company's usual employment practices. There have been no changes to Dr. Debrabandere's compensation at this time.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

OSIRIS THERAPEUTICS, INC.

Dated: December 6, 2013

By: */s/ PHILIP R. JACOBY, JR.*
Philip R. Jacoby, Jr.
Chief Financial Officer